Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis

Review of placebo, and active controlled studies for anti-TNFs concluded that a 12% absolute difference on ACR20 response would be an appropriate non-inferiority margin for evaluating a new treatment against an established treatment for rheumatoid arthritis.

Arthritis & Rheumatology